WO2013136254A1 - Heterocyclyl compounds - Google Patents

Heterocyclyl compounds Download PDF

Info

Publication number: WO2013136254A1
Authority: WO; WIPO (PCT)
Prior art keywords: alkyl; group; substituted; cycloalkyl; unsubstituted
Prior art date: 2012-03-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

PCT/IB2013/051915

Other languages

English (en)

French (fr)

Inventor

Bhavesh Dave

Rakesh Kumar Banerjee

Samiron Phukan

Abhijit Datta Khoje

Rajkumar HANGARGE

Jitendra Sambhaji Jadhav

Venkata P. Palle

Rajender Kumar Kamboj

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Lupin Ltd

Original Assignee

Lupin Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-14

Filing date

2013-03-11

Publication date

2013-09-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013136254(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-11 Priority to DK13711973.1T priority Critical patent/DK2834236T3/da

2013-03-11 Priority to CN201380014210.XA priority patent/CN104203947A/zh

2013-03-11 Priority to CA2865167A priority patent/CA2865167C/en

2013-03-11 Priority to IN1754MUN2014 priority patent/IN2014MN01754A/en

2013-03-11 Priority to CUP2014000109A priority patent/CU24335B1/es

2013-03-11 Priority to JP2014561567A priority patent/JP6093384B2/ja

2013-03-11 Priority to US14/385,106 priority patent/US9573944B2/en

2013-03-11 Priority to MA37405A priority patent/MA37405A1/fr

2013-03-11 Priority to HK15106571.7A priority patent/HK1206020B/en

2013-03-11 Priority to ES13711973T priority patent/ES2741896T3/es

2013-03-11 Priority to NZ629442A priority patent/NZ629442A/en

2013-03-11 Priority to AP2014008008A priority patent/AP3834A/en

2013-03-11 Priority to SG11201405007QA priority patent/SG11201405007QA/en

2013-03-11 Application filed by Lupin Ltd filed Critical Lupin Ltd

2013-03-11 Priority to EA201491671A priority patent/EA029768B1/ru

2013-03-11 Priority to AU2013234014A priority patent/AU2013234014B2/en

2013-03-11 Priority to MX2014010925A priority patent/MX355526B/es

2013-03-11 Priority to EP13711973.1A priority patent/EP2834236B1/en

2013-03-11 Priority to KR1020197017334A priority patent/KR102240101B1/ko

2013-03-11 Priority to KR1020147028556A priority patent/KR20140138910A/ko

2013-03-11 Priority to UAA201411011A priority patent/UA114906C2/uk

2013-09-19 Publication of WO2013136254A1 publication Critical patent/WO2013136254A1/en

2014-08-18 Priority to TNP2014000357A priority patent/TN2014000357A1/fr

2014-09-09 Priority to IL234559A priority patent/IL234559A/en

2014-09-12 Priority to PH12014502040A priority patent/PH12014502040B1/en

2014-09-14 Anticipated expiration legal-status Critical

2014-10-06 Priority to CR20140464A priority patent/CR20140464A/es

2017-01-06 Priority to US15/400,627 priority patent/US9827247B2/en

Status Ceased legal-status Critical Current

Links

0 *C(C(N(*)C(Nc1ccccc1)=C1C(N2*)=O)=O)=C1N(c1ccccc1)C2=O Chemical compound *C(C(N(*)C(Nc1ccccc1)=C1C(N2*)=O)=O)=C1N(c1ccccc1)C2=O 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

R 1 is selected from the group consisting of hydrogen, substituted- or unsubstituted-alkyl, substituted- or unsubstituted- cycloalkyl, and substituted- or unsubstituted- heterocyclyl;
alkenyl as used herein, means an 'alkyl' group as defined hereinabove containing 2 to 20 carbon atoms and containing at least one double bond.
alkenyl include, but are not limited to, pent-2-enyl, hex-3-enyl, allyl, vinyl, and the like.
Step-1 Synthesis of 3-(3-bromophenyl) oxetan-3-ol
Azetidin-3-ol hydrochloride (1.0 g, 9.13 mmol) was taken in DMSO and l-fluoro-3- nitrobenzene (1.0 g, 7.09 mmol) was added followed by K 2 C0 3 (2.449 g, 17.72 mmol).
the reaction mixture was heated to 100 °C for 16 hrs. After completion of the reaction, the reaction mixture was cooled and poured into water which was then extracted with ethyl acetate (3 x 8ml). The organic layers were combined, washed with water and brine, dried over sodium sulfate, and concentrated under vacuum.

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Radiology & Medical Imaging (AREA)
Pathology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)

PCT/IB2013/051915 2012-03-14 2013-03-11 Heterocyclyl compounds Ceased WO2013136254A1 (en)

Priority Applications (25)

Application Number	Priority Date	Filing Date	Title
UAA201411011A UA114906C2 (uk)	2012-03-14	2013-03-11	Гетероциклільні сполуки як інгібітори мек
EA201491671A EA029768B1 (ru)	2012-03-14	2013-03-11	Гетероциклильные соединения
CA2865167A CA2865167C (en)	2012-03-14	2013-03-11	Heterocyclyl compounds
IN1754MUN2014 IN2014MN01754A (2)	2012-03-14	2013-03-11
CUP2014000109A CU24335B1 (es)	2012-03-14	2013-03-11	Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
JP2014561567A JP6093384B2 (ja)	2012-03-14	2013-03-11	ヘテロシクリル化合物
US14/385,106 US9573944B2 (en)	2012-03-14	2013-03-11	Heterocyclyl compounds
MA37405A MA37405A1 (fr)	2012-03-14	2013-03-11	Composés hétérocyclyle
HK15106571.7A HK1206020B (en)	2012-03-14	2013-03-11	Heterocyclyl compounds
ES13711973T ES2741896T3 (es)	2012-03-14	2013-03-11	Compuestos de heterociclilo
NZ629442A NZ629442A (en)	2012-03-14	2013-03-11	Heterocyclyl compounds as mek inhibitors
AP2014008008A AP3834A (en)	2012-03-14	2013-03-11	Heterocyclyl compounds
SG11201405007QA SG11201405007QA (en)	2012-03-14	2013-03-11	Heterocyclyl compounds
DK13711973.1T DK2834236T3 (da)	2012-03-14	2013-03-11	Heterocyclylforbindelser
MX2014010925A MX355526B (es)	2012-03-14	2013-03-11	Compuesto de heterociclilo.
KR1020147028556A KR20140138910A (ko)	2012-03-14	2013-03-11	헤테로사이클릴 화합물
AU2013234014A AU2013234014B2 (en)	2012-03-14	2013-03-11	Heterocyclyl compounds
EP13711973.1A EP2834236B1 (en)	2012-03-14	2013-03-11	Heterocyclyl compounds
KR1020197017334A KR102240101B1 (ko)	2012-03-14	2013-03-11	헤테로사이클릴 화합물
CN201380014210.XA CN104203947A (zh)	2012-03-14	2013-03-11	杂环基化合物
TNP2014000357A TN2014000357A1 (en)	2012-03-14	2014-08-18	Heterocyclyl compounds
IL234559A IL234559A (en)	2012-03-14	2014-09-09	Heterocyclic compounds
PH12014502040A PH12014502040B1 (en)	2012-03-14	2014-09-12	Heterocyclyl compounds
CR20140464A CR20140464A (es)	2012-03-14	2014-10-06	Compuestos de heterociclilo
US15/400,627 US9827247B2 (en)	2012-03-14	2017-01-06	Heterocyclyl compounds

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN288/KOL/2012		2012-03-14
IN288KO2012		2012-03-14

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
US14/385,106 A-371-Of-International US9573944B2 (en)	2012-03-14	2013-03-11	Heterocyclyl compounds
US15/400,627 Continuation US9827247B2 (en)	2012-03-14	2017-01-06	Heterocyclyl compounds

Publications (1)

Publication Number	Publication Date
WO2013136254A1 true WO2013136254A1 (en)	2013-09-19

Family

ID=47997632

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PCT/IB2013/051915 Ceased WO2013136254A1 (en)	2012-03-14	2013-03-11	Heterocyclyl compounds
PCT/IB2013/051908 Ceased WO2013136249A1 (en)	2012-03-14	2013-03-11	Heterocyclyl compounds as mek inhibitors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PCT/IB2013/051908 Ceased WO2013136249A1 (en)	2012-03-14	2013-03-11	Heterocyclyl compounds as mek inhibitors

Country Status (35)

Country	Link
US (5)	US9428499B2 (2)
EP (2)	EP2834236B1 (2)
JP (3)	JP6093384B2 (2)
KR (4)	KR102241111B1 (2)
CN (4)	CN108383836B (2)
AP (2)	AP3859A (2)
AU (4)	AU2013234009B2 (2)
BR (1)	BR112014022713B1 (2)
CA (2)	CA2865167C (2)
CL (2)	CL2014002412A1 (2)
CO (2)	CO7160029A2 (2)
CR (2)	CR20140464A (2)
CU (2)	CU24335B1 (2)
DK (2)	DK2834236T3 (2)
DO (2)	DOP2014000204A (2)
EA (2)	EA029768B1 (2)
ES (2)	ES2741896T3 (2)
GE (2)	GEP201706774B (2)
GT (2)	GT201400195A (2)
IL (2)	IL234559A (2)
IN (2)	IN2014MN01754A (2)
MA (2)	MA37405A1 (2)
MX (3)	MX355474B (2)
MY (2)	MY174188A (2)
NI (2)	NI201400107A (2)
NZ (2)	NZ629432A (2)
PE (2)	PE20141974A1 (2)
PH (2)	PH12014502040B1 (2)
PL (1)	PL2834237T3 (2)
SG (2)	SG11201405006PA (2)
TN (2)	TN2014000357A1 (2)
TR (1)	TR201811976T4 (2)
UA (2)	UA114907C2 (2)
WO (2)	WO2013136254A1 (2)
ZA (1)	ZA201406186B (2)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016009306A1 (en) *	2014-07-15	2016-01-21	Lupin Limited	Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) *	2014-09-04	2016-03-10	Lupin Limited	Pyridopyrimidine derivatives as mek inhibitors
WO2020188015A1 (en)	2019-03-21	2020-09-24	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020254451A1 (en)	2019-06-19	2020-12-24	Boehringer Ingelheim International Gmbh	Anticancer combination therapy
WO2021089791A1 (en)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
WO2021245051A1 (en)	2020-06-02	2021-12-09	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2022214594A1 (en)	2021-04-09	2022-10-13	Boehringer Ingelheim International Gmbh	Anticancer therapy
WO2023099620A1 (en)	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
WO2023099592A1 (en)	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099624A1 (en)	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099608A1 (en)	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en)	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US11814380B2 (en)	2017-12-21	2023-11-14	Boehringer Ingelheim International Gmbh	Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
US12053473B2 (en)	2016-12-22	2024-08-06	Boehringer Ingelheim International Gmbh	Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
WO2024246099A1 (en)	2023-05-30	2024-12-05	Boehringer Ingelheim International Gmbh	Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
NZ629432A (en)	2012-03-14	2017-01-27	Lupin Ltd	Heterocyclyl compounds as mek inhibitors
RS58514B1 (sr)	2012-06-13	2019-04-30	Incyte Holdings Corp	Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en)	2013-04-19	2023-02-03	Incyte Holdings Corp	Bicyclic heterocycles as fgfr inhibitors
JP6403172B2 (ja) *	2013-10-25	2018-10-10	シャンハイヘンルイファーマスーティカルカンパニーリミテッドＳｈａｎｇｈａｉＨｅｎｇｒｕｉＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh)	2015-02-20	2020-12-11	美商英塞特公司	作為fgfr抑制劑之雙環雜環
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AU2019262579B2 (en)	2018-05-04	2024-09-12	Incyte Corporation	Salts of an FGFR inhibitor
HRP20241288T1 (hr)	2018-05-04	2024-12-06	Incyte Corporation	Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
BR112022001678A2 (pt) *	2019-07-30	2022-05-03	Edvince Ab	Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes
EP3797899A1 (de)	2019-09-27	2021-03-31	Primetals Technologies Austria GmbH	Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en)	2019-10-14	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja)	2019-12-04	2026-03-18	インサイト・コーポレイション	Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
TWI825637B (zh) *	2021-03-31	2023-12-11	美商輝瑞股份有限公司	啶－１，６（２ｈ，７ｈ）－二酮
WO2022221170A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022221866A1 (en) *	2021-04-16	2022-10-20	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
US12280055B2 (en)	2021-05-27	2025-04-22	Mirati Therapeutics, Inc.	Combination therapies
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
CN114605408B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573581B (zh) *	2022-03-30	2023-09-01	沈阳药科大学	5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573582B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
US11878958B2 (en)	2022-05-25	2024-01-23	Ikena Oncology, Inc.	MEK inhibitors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005121142A1 (en) *	2004-06-11	2005-12-22	Japan Tobacco Inc.	5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US5019369A (en)	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
UA72612C2 (en) *	2000-07-06	2005-03-15		Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) *	2001-05-18	2004-11-30	Cell Therapeutics, Inc.	Pyridopyrimidine compounds and their uses
GB0129099D0 (en)	2001-12-05	2002-01-23	Astrazeneca Ab	Chemical compounds
MXPA04005939A (es) *	2002-01-22	2005-01-25	Warner Lambert Co	2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
CN1905873A (zh)	2003-11-19	2007-01-31	阵列生物制药公司	Mek的杂环抑制剂及其使用方法
US7378423B2 (en)	2004-06-11	2008-05-27	Japan Tobacco Inc.	Pyrimidine compound and medical use thereof
CA2761108A1 (en)	2009-04-21	2010-10-28	Novartis Ag	Heterocyclic compounds as mek inhibitors
NZ629432A (en) *	2012-03-14	2017-01-27	Lupin Ltd	Heterocyclyl compounds as mek inhibitors

2013
- 2013-03-11 NZ NZ629432A patent/NZ629432A/en unknown
- 2013-03-11 AP AP2014008009A patent/AP3859A/en active
- 2013-03-11 ES ES13711973T patent/ES2741896T3/es active Active
- 2013-03-11 WO PCT/IB2013/051915 patent/WO2013136254A1/en not_active Ceased
- 2013-03-11 UA UAA201411014A patent/UA114907C2/uk unknown
- 2013-03-11 MX MX2014010928A patent/MX355474B/es active IP Right Grant
- 2013-03-11 MX MX2018003665A patent/MX366426B/es unknown
- 2013-03-11 EA EA201491671A patent/EA029768B1/ru unknown
- 2013-03-11 MX MX2014010925A patent/MX355526B/es active IP Right Grant
- 2013-03-11 AP AP2014008008A patent/AP3834A/en active
- 2013-03-11 MA MA37405A patent/MA37405A1/fr unknown
- 2013-03-11 NZ NZ629442A patent/NZ629442A/en not_active IP Right Cessation
- 2013-03-11 PL PL13712929T patent/PL2834237T3/pl unknown
- 2013-03-11 PE PE2014001400A patent/PE20141974A1/es active IP Right Grant
- 2013-03-11 KR KR1020197024543A patent/KR102241111B1/ko active Active
- 2013-03-11 IN IN1754MUN2014 patent/IN2014MN01754A/en unknown
- 2013-03-11 CU CUP2014000109A patent/CU24335B1/es unknown
- 2013-03-11 SG SG11201405006PA patent/SG11201405006PA/en unknown
- 2013-03-11 CA CA2865167A patent/CA2865167C/en not_active Expired - Fee Related
- 2013-03-11 CN CN201810086896.8A patent/CN108383836B/zh active Active
- 2013-03-11 WO PCT/IB2013/051908 patent/WO2013136249A1/en not_active Ceased
- 2013-03-11 AU AU2013234009A patent/AU2013234009B2/en active Active
- 2013-03-11 KR KR1020147028556A patent/KR20140138910A/ko not_active Ceased
- 2013-03-11 EP EP13711973.1A patent/EP2834236B1/en active Active
- 2013-03-11 US US14/385,092 patent/US9428499B2/en active Active
- 2013-03-11 DK DK13711973.1T patent/DK2834236T3/da active
- 2013-03-11 TR TR2018/11976T patent/TR201811976T4/tr unknown
- 2013-03-11 CN CN201380023296.2A patent/CN104271577A/zh active Pending
- 2013-03-11 JP JP2014561567A patent/JP6093384B2/ja active Active
- 2013-03-11 CA CA2865164A patent/CA2865164C/en active Active
- 2013-03-11 KR KR1020197017334A patent/KR102240101B1/ko not_active Expired - Fee Related
- 2013-03-11 CU CUP2014000110A patent/CU24272B1/xx unknown
- 2013-03-11 KR KR1020147028557A patent/KR20140138911A/ko not_active Ceased
- 2013-03-11 CN CN201710823363.9A patent/CN107698585A/zh active Pending
- 2013-03-11 GE GEAP201313596A patent/GEP201706774B/en unknown
- 2013-03-11 GE GEAP201313595A patent/GEP201706671B/en unknown
- 2013-03-11 PE PE2014001399A patent/PE20141973A1/es active IP Right Grant
- 2013-03-11 SG SG11201405007QA patent/SG11201405007QA/en unknown
- 2013-03-11 CN CN201380014210.XA patent/CN104203947A/zh active Pending
- 2013-03-11 MY MYPI2014002639A patent/MY174188A/en unknown
- 2013-03-11 IN IN1755MUN2014 patent/IN2014MN01755A/en unknown
- 2013-03-11 JP JP2014561564A patent/JP6431770B2/ja active Active
- 2013-03-11 ES ES13712929T patent/ES2684517T3/es active Active
- 2013-03-11 EP EP13712929.2A patent/EP2834237B1/en active Active
- 2013-03-11 US US14/385,106 patent/US9573944B2/en active Active
- 2013-03-11 MA MA37400A patent/MA37400B1/fr unknown
- 2013-03-11 EA EA201491672A patent/EA028232B1/ru unknown
- 2013-03-11 AU AU2013234014A patent/AU2013234014B2/en not_active Ceased
- 2013-03-11 BR BR112014022713-6A patent/BR112014022713B1/pt active IP Right Grant
- 2013-03-11 MY MYPI2014002638A patent/MY175950A/en unknown
- 2013-03-11 DK DK13712929.2T patent/DK2834237T3/en active
- 2013-03-11 UA UAA201411011A patent/UA114906C2/uk unknown
2014
- 2014-08-18 TN TNP2014000357A patent/TN2014000357A1/fr unknown
- 2014-08-18 TN TNP2014000356A patent/TN2014000356A1/fr unknown
- 2014-08-22 ZA ZA2014/06186A patent/ZA201406186B/en unknown
- 2014-09-09 IL IL234559A patent/IL234559A/en active IP Right Grant
- 2014-09-09 IL IL234560A patent/IL234560A/en active IP Right Grant
- 2014-09-10 DO DO2014000204A patent/DOP2014000204A/es unknown
- 2014-09-10 DO DO2014000203A patent/DOP2014000203A/es unknown
- 2014-09-11 NI NI201400107A patent/NI201400107A/es unknown
- 2014-09-11 NI NI201400108A patent/NI201400108A/es unknown
- 2014-09-12 CL CL2014002412A patent/CL2014002412A1/es unknown
- 2014-09-12 CL CL2014002411A patent/CL2014002411A1/es unknown
- 2014-09-12 PH PH12014502040A patent/PH12014502040B1/en unknown
- 2014-09-12 PH PH12014502041A patent/PH12014502041B1/en unknown
- 2014-09-12 GT GT201400195A patent/GT201400195A/es unknown
- 2014-09-12 GT GT201400196A patent/GT201400196A/es unknown
- 2014-10-06 CR CR20140464A patent/CR20140464A/es unknown
- 2014-10-06 CO CO14221195A patent/CO7160029A2/es unknown
- 2014-10-06 CR CR20140463A patent/CR20140463A/es unknown
- 2014-10-06 CO CO14221191A patent/CO7170131A2/es unknown
2016
- 2016-07-25 US US15/218,980 patent/US9555035B2/en active Active
- 2016-12-22 US US15/388,327 patent/US9969731B2/en active Active
2017
- 2017-01-06 US US15/400,627 patent/US9827247B2/en active Active
- 2017-01-25 AU AU2017200493A patent/AU2017200493B2/en active Active
2018
- 2018-04-12 AU AU2018202568A patent/AU2018202568B2/en active Active
- 2018-05-01 JP JP2018088389A patent/JP6630771B2/ja active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005121142A1 (en) *	2004-06-11	2005-12-22	Japan Tobacco Inc.	5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016009306A1 (en) *	2014-07-15	2016-01-21	Lupin Limited	Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) *	2014-09-04	2016-03-10	Lupin Limited	Pyridopyrimidine derivatives as mek inhibitors
US12053473B2 (en)	2016-12-22	2024-08-06	Boehringer Ingelheim International Gmbh	Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
US11814380B2 (en)	2017-12-21	2023-11-14	Boehringer Ingelheim International Gmbh	Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
WO2020188015A1 (en)	2019-03-21	2020-09-24	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020254451A1 (en)	2019-06-19	2020-12-24	Boehringer Ingelheim International Gmbh	Anticancer combination therapy
WO2021089791A1 (en)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
WO2021245051A1 (en)	2020-06-02	2021-12-09	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2021245055A1 (en)	2020-06-02	2021-12-09	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2022214594A1 (en)	2021-04-09	2022-10-13	Boehringer Ingelheim International Gmbh	Anticancer therapy
WO2023099624A1 (en)	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099608A1 (en)	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en)	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099592A1 (en)	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099620A1 (en)	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
WO2024246099A1 (en)	2023-05-30	2024-12-05	Boehringer Ingelheim International Gmbh	Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma

Also Published As

Publication number	Publication date
AP2014008009A0 (en)	2014-10-31
DK2834237T3 (en)	2018-08-27
UA114906C2 (uk)	2017-08-28
EA028232B1 (ru)	2017-10-31
EP2834237B1 (en)	2018-06-06
JP6431770B2 (ja)	2018-11-28
US9428499B2 (en)	2016-08-30
KR20190073597A (ko)	2019-06-26
IL234560A (en)	2017-06-29
AU2018202568A1 (en)	2018-05-10
IN2014MN01755A (2)	2015-07-03
AP3859A (en)	2016-10-31
US20150133424A1 (en)	2015-05-14
NZ629432A (en)	2017-01-27
KR20140138911A (ko)	2014-12-04
CU20140110A7 (es)	2014-11-27
EP2834237A1 (en)	2015-02-11
CN108383836B (zh)	2021-11-12
HK1206020A1 (en)	2015-12-31
CN104271577A (zh)	2015-01-07
MA37400A1 (fr)	2016-05-31
MX2014010925A (es)	2015-04-10
CU24335B1 (es)	2018-04-03
CL2014002411A1 (es)	2015-04-06
US9969731B2 (en)	2018-05-15
US20160331753A1 (en)	2016-11-17
NZ629442A (en)	2016-12-23
PE20141973A1 (es)	2014-12-12
US9827247B2 (en)	2017-11-28
PH12014502041A1 (en)	2014-11-24
PL2834237T3 (pl)	2018-11-30
US20170101408A1 (en)	2017-04-13
DOP2014000203A (es)	2015-02-15
UA114907C2 (uk)	2017-08-28
CR20140463A (es)	2014-11-28
HK1202538A1 (en)	2015-10-02
ZA201406186B (en)	2016-06-29
SG11201405007QA (en)	2014-10-30
JP2018115215A (ja)	2018-07-26
JP2015509975A (ja)	2015-04-02
AU2017200493B2 (en)	2018-03-29
SG11201405006PA (en)	2014-10-30
GT201400195A (es)	2017-11-09
CA2865164C (en)	2021-06-08
IN2014MN01754A (2)	2015-07-03
DOP2014000204A (es)	2015-02-15
ES2741896T3 (es)	2020-02-12
MX355474B (es)	2018-04-16
AU2013234009B2 (en)	2016-10-27
KR20190100472A (ko)	2019-08-28
GT201400196A (es)	2017-09-28
MX2014010928A (es)	2015-04-10
AU2017200493A1 (en)	2017-02-16
EP2834236A1 (en)	2015-02-11
TR201811976T4 (tr)	2018-09-21
PE20141974A1 (es)	2014-12-12
CN108383836A (zh)	2018-08-10
NI201400108A (es)	2014-11-28
PH12014502040A1 (en)	2014-11-24
CR20140464A (es)	2014-11-28
BR112014022713A2 (2)	2017-06-20
US9555035B2 (en)	2017-01-31
CO7160029A2 (es)	2015-01-15
EA201491672A1 (ru)	2014-12-30
CA2865164A1 (en)	2013-09-19
CA2865167C (en)	2019-08-06
EP2834236B1 (en)	2019-05-22
TN2014000357A1 (en)	2015-12-21
AU2013234009A1 (en)	2014-09-25
EA201491671A1 (ru)	2014-12-30
CO7170131A2 (es)	2015-01-28
NI201400107A (es)	2014-11-26
MX366426B (es)	2019-07-08
CA2865167A1 (en)	2013-09-19
CL2014002412A1 (es)	2015-03-06
GEP201706671B (en)	2017-05-25
MY174188A (en)	2020-03-12
AU2018202568B2 (en)	2019-05-09
JP2015514056A (ja)	2015-05-18
AP2014008008A0 (en)	2014-10-31
BR112014022713B1 (pt)	2021-09-08
AU2013234014B2 (en)	2017-02-02
CU20140109A7 (es)	2014-11-27
WO2013136249A1 (en)	2013-09-19
US20150299186A1 (en)	2015-10-22
MX355526B (es)	2018-04-20
JP6630771B2 (ja)	2020-01-15
AP3834A (en)	2016-09-30
IL234559A (en)	2017-06-29
KR102240101B1 (ko)	2021-04-14
MA37400B1 (fr)	2019-11-29
GEP201706774B (en)	2017-11-27
PH12014502040B1 (en)	2014-11-24
PH12014502041B1 (en)	2014-11-24
US20170112840A1 (en)	2017-04-27
US9573944B2 (en)	2017-02-21
KR102241111B1 (ko)	2021-04-15
DK2834236T3 (da)	2019-08-26
JP6093384B2 (ja)	2017-03-08
ES2684517T3 (es)	2018-10-03
CN107698585A (zh)	2018-02-16
MA37405A1 (fr)	2016-03-31
MY175950A (en)	2020-07-16
TN2014000356A1 (en)	2015-12-21
KR20140138910A (ko)	2014-12-04
CN104203947A (zh)	2014-12-10
AU2013234014A1 (en)	2014-09-25
EA029768B1 (ru)	2018-05-31
CU24272B1 (es)	2017-08-08

Legal Events

Date	Code	Title	Description
2013-11-06	121	Ep: the epo has been informed by wipo that ep was designated in this application	Ref document number: 13711973 Country of ref document: EP Kind code of ref document: A1
2014-08-20	ENP	Entry into the national phase	Ref document number: 2865167 Country of ref document: CA
2014-08-27	WWE	Wipo information: entry into national phase	Ref document number: DZP2014000501 Country of ref document: DZ
2014-08-28	WWE	Wipo information: entry into national phase	Ref document number: IDP00201405124 Country of ref document: ID
2014-09-11	ENP	Entry into the national phase	Ref document number: 2014561567 Country of ref document: JP Kind code of ref document: A
2014-09-11	WWE	Wipo information: entry into national phase	Ref document number: P957/2014 Country of ref document: AE Ref document number: 001400-2014 Country of ref document: PE Ref document number: MX/A/2014/010925 Country of ref document: MX
2014-09-12	WWE	Wipo information: entry into national phase	Ref document number: 2014002412 Country of ref document: CL Ref document number: 14385106 Country of ref document: US
2014-09-15	NENP	Non-entry into the national phase	Ref country code: DE
2014-09-25	ENP	Entry into the national phase	Ref document number: 2013234014 Country of ref document: AU Date of ref document: 20130311 Kind code of ref document: A
2014-10-06	WWE	Wipo information: entry into national phase	Ref document number: 14221191 Country of ref document: CO Ref document number: CR2014-000464 Country of ref document: CR
2014-10-09	WWE	Wipo information: entry into national phase	Ref document number: 201491671 Country of ref document: EA Ref document number: A201411011 Country of ref document: UA
2014-10-10	ENP	Entry into the national phase	Ref document number: 20147028556 Country of ref document: KR Kind code of ref document: A
2014-10-13	ENP	Entry into the national phase	Ref document number: 13596 Country of ref document: GE Kind code of ref document: P
2014-10-13	WWE	Wipo information: entry into national phase	Ref document number: 2013711973 Country of ref document: EP
2014-10-21	REG	Reference to national code	Ref country code: BR Ref legal event code: B01A Ref document number: 112014022398 Country of ref document: BR
2017-06-20	ENP	Entry into the national phase	Ref document number: 112014022398 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140910